MAPS Receives $4,140,000 Grant from Psychedelic Science Funders Collaborative (PSFC)

The generosity of our supporters continues to humble us. The Psychedelic Science Funders Collaborative (PSFC) has generously provided a $4,140,000 grant to support the expansion of our work. PSFC is a non-profit network of philanthropists dedicated to supporting research and clinical trials with psychedelic medicines and patient access to these treatments. PSFC was born in 2017 out of a realization that psychedelic medicine has the potential to make an enormous impact and has an achievable path to regulatory approval, but has been systemically underfunded. With this grant to MAPS, PSFC is making its first big contribution.

“PSFC is committed to supporting MAPS in its quest to make MDMA-assisted psychotherapy legal and available for the millions of people suffering from PTSD around the globe. We applaud the incredible progress so far and are delighted to support the work to come,” says Joe Green, the President and Co-Founder of PSFC. Graham Boyd, Executive Director and Co-Founder of PSFC, adds: “We believe that regulatory approval of MDMA will be catalytic, clearing a path for other psychedelic medicines to address depression, addiction, and a range of other mental health conditions.”

The PSFC grant will advance some of the key objectives of the overall MAPS campaign to gain regulatory approval for MDMA and to ensure that patients have access to this critical medicine.

  • $2,900,000 from PSFC for production of pharmaceutical-grade MDMA, made under current Good Manufacturing Practices (GMP) in a certified laboratory. A reliable supply of MDMA will support the clinical trials in the United States and Europe, as well as provide a supply for researchers around the globe. PSFC is also committed to helping MAPS scale production capacity to supply patient needs in the years to come.
  • $1,100,000 from an anonymous PSFC member for European Medicines Agency (EMA)-regulated Phase 2 and Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD. MAPS and PSFC hope that approval in Europe and the United States will quickly translate into approval from other nations around the globe.
  • $50,000 from PSFC to support MAPS’ work with Dr. Atul Pande. Dr. Pande will provide extended advisory support for the MAPS-sponsored clinical program and in planning for delivery of MDMA-assisted psychotherapy to patients. Dr. Pande has been involved with securing FDA and European Medicines Agency approval for over a dozen psychiatric drugs including Prozac, Lamictal, Lyrica, and Wellbutrin during his two decades of experience in roles such as Senior Vice President for Neurosciences at GlaxoSmithKline, Chief Medical Officer at PureTech Health, and others at large and small pharmaceutical companies.
  • $50,000 from PSFC to support raising MAPS staff salaries. PSFC is excited to help MAPS staff receive compensation in line with the extraordinary work they are doing.
  • $40,000 from PSFC for our upcoming Therapy Training Event for Communities of Color in Kentucky. PSFC believes strongly in the need to ensure access to treatment for underserved populations. In bringing forward a therapy that helps heal trauma, it is particularly important to ensure that therapists are trained who come from and serve in communities especially impacted by trauma, including communities of color.

Learn more about the Psychedelic Science Funders Collaborative (PSFC)